Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 24, 2017

DrugPatentWatch Database Preview


« Back to Dashboard

What is the patent landscape for Hydroxyzine, and when can generic versions of Hydroxyzine launch?

Hydroxyzine is a drug marketed by Baxter Hlthcare, Vintage, Eci Pharms Llc, Elite Labs Inc, Hetero Labs Ltd Iii, Pharmafair, Luitpold, Amneal Pharm, Mutual Pharm, Solopak, Hi Tech Pharma, Ivax Pharms, Invagen Pharms, Hospira, Halsey, Pliva, Kv Pharm, Nuvo Pharm Inc, Purepac Pharm, Usl Pharma, Watson Labs, Fresenius Kabi Usa, Quantum Pharmics, Northstar Hlthcare, Sandoz, Wyeth Ayerst, Able, Sun Pharm Inds, Actavis Elizabeth, Aurolife Pharma Llc, Altana, Silarx Pharms Inc, Prinston Inc, Mylan, Heritage Pharma, Sti Pharma Llc, Alpharma Us Pharms, Kvk Tech, Vintage Pharms, Smith And Nephew, Wockhardt, Superpharm, Sun Pharm Inds Inc, Par Pharm, Impax Labs Inc, Ivax Sub Teva Pharms, Barr, Vangard, and Duramed Pharms Barr. and is included in one hundred and thirty-eight NDAs.

The generic ingredient in HYDROXYZINE is hydroxyzine pamoate. There are nineteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the hydroxyzine pamoate profile page.

Summary for Tradename: HYDROXYZINE

Bulk Api Vendors: see list32
Clinical Trials: see list4
Patent Applications: see list4,414
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:HYDROXYZINE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
hydroxyzine hydrochloride
TABLET;ORAL081151-001Mar 18, 1994DISCNNoNo► Subscribe► Subscribe
Heritage Pharma
hydroxyzine hydrochloride
TABLET;ORAL204279-001Aug 20, 2014ABRXNoNo► Subscribe► Subscribe
Nuvo Pharm Inc
hydroxyzine hydrochloride
TABLET;ORAL207121-001Mar 29, 2017ABRXNoNo► Subscribe► Subscribe
hydroxyzine hydrochloride
TABLET;ORAL088617-001Jan 10, 1986ABRXNoYes► Subscribe► Subscribe
hydroxyzine pamoate
CAPSULE;ORAL088392-001Sep 19, 1983DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Find generic sources and suppliers
  • Formulary management

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus